Published in Women's Health Weekly, December 19th, 2002
The trial will evaluate a therapeutic vaccine containing a HER-2 derived antigen designed by UAB and Ohio State University scientists together with Galenica's proprietary immune enhancer GPI-0100 to treat patients with HER-2 overexpressing cancers.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.